ArticleMedical oncology (Northwood, London, England)2025
Harnessing nature's arsenal: next steps for garlic-based therapies in acute myeloid leukemia.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This letter commends the recent study by Abdelkarim et al. on the pro-apoptotic effects of an Allium sativum (garlic) extract in acute myeloid leukemia (AML). While acknowledging the significance of their ex vivo findings on primary patient cells, we propose several key considerations to strengthen the translational potential of this research. Firstly, we emphasize the need for standardized phytochemical characterization of the complex extract to ensure reproducibility. Additionally, we suggest expanding the mechanistic investigation to include the extrinsic apoptosis pathway and direct measurement of reactive oxygen species. Furthermore, we discuss strategies to enhance the targeting of resistant leukemia stem cell populations, such as prolonged exposure or combination therapy with venetoclax. Finally, we advocate for in vivo validation using patient-derived xenograft models to evaluate efficacy within a physiologically relevant microenvironment. Addressing these points will be crucial for harnessing the full potential of Allium sativum as a complementary therapy in AML.
Indexed as
Identifiers
41452404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.